Indication: Type 2 Diabetes Mellitus (T2DM)

A double-blind, randomized, placebo-controlled, parallel group trial to evaluate the efficacy and safety of empagliflozin and linagliptin over 26 weeks, with a double-blind active treatment safety extension period up to 52 weeks, in children and adolescen

Sub-indication: Type 2 Diabetes Mellitus (T2DM)

Drug Study

Principal Investigator: Kupper Wintergerst, M.D.
Norton Children's Endocrinology, affiliated with the UofL School of Medicine

Sponsor: Boehringer Ingelheim

Search our entire site.